NFP Retirement Inc. Buys 662 Shares of Gilead Sciences, Inc. $GILD

NFP Retirement Inc. lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,077 shares of the biopharmaceutical company’s stock after acquiring an additional 662 shares during the period. NFP Retirement Inc.’s holdings in Gilead Sciences were worth $3,335,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc grew its stake in Gilead Sciences by 7.1% in the second quarter. Ensign Peak Advisors Inc now owns 2,297,702 shares of the biopharmaceutical company’s stock valued at $254,746,000 after purchasing an additional 152,685 shares during the last quarter. Quilter Plc grew its position in shares of Gilead Sciences by 0.5% in the 2nd quarter. Quilter Plc now owns 33,871 shares of the biopharmaceutical company’s stock worth $3,755,000 after buying an additional 180 shares during the last quarter. Empirical Finance LLC raised its stake in shares of Gilead Sciences by 0.6% during the 2nd quarter. Empirical Finance LLC now owns 43,664 shares of the biopharmaceutical company’s stock worth $4,841,000 after acquiring an additional 277 shares in the last quarter. Nicholas Wealth LLC. lifted its position in Gilead Sciences by 21.7% during the second quarter. Nicholas Wealth LLC. now owns 10,656 shares of the biopharmaceutical company’s stock valued at $1,181,000 after acquiring an additional 1,902 shares during the last quarter. Finally, Alteri Wealth LLC boosted its stake in Gilead Sciences by 11.5% in the second quarter. Alteri Wealth LLC now owns 5,181 shares of the biopharmaceutical company’s stock valued at $574,000 after acquiring an additional 535 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the sale, the executive vice president owned 43,676 shares of the company’s stock, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the transaction, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. The trade was a 1.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 125,146 shares of company stock worth $15,148,441 over the last 90 days. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Up 0.7%

Shares of GILD stock opened at $128.07 on Thursday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a 50 day moving average of $118.09 and a 200 day moving average of $113.29. Gilead Sciences, Inc. has a twelve month low of $87.77 and a twelve month high of $128.10. The stock has a market cap of $158.89 billion, a P/E ratio of 25.51, a P/E/G ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter last year, the business earned $2.02 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GILD. Argus raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Truist Financial reaffirmed a “buy” rating and issued a $145.00 price objective (up from $127.00) on shares of Gilead Sciences in a research report on Monday, November 3rd. Morgan Stanley lifted their target price on shares of Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Gilead Sciences in a research note on Monday, November 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $129.13.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.